Zacks Investment Research cut shares of Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) from a hold rating to a sell rating in a report published on Monday morning.

According to Zacks, “Ekso Bionics Holdings, Inc. is engaged in designing, developing and selling wearable robots or exoskeletons for the medical, military, industrial and consumer markets. The company’s operating segment consists of Engineering Services and Medical segments. It operates primarily in North America, Western Europe, the Middle East and South Africa. Ekso Bionics Holdings, Inc. is headquartered in Richmond, California. “

Ekso Bionics Holdings (EKSO) opened at $1.91 on Monday. Ekso Bionics Holdings has a 52 week low of $0.99 and a 52 week high of $4.90. The company has a current ratio of 6.09, a quick ratio of 5.73 and a debt-to-equity ratio of 0.18.

Ekso Bionics Holdings (NASDAQ:EKSO) last issued its quarterly earnings results on Wednesday, November 8th. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.05). The business had revenue of $1.60 million for the quarter, compared to the consensus estimate of $2.40 million. Ekso Bionics Holdings had a negative return on equity of 323.00% and a negative net margin of 343.53%. research analysts expect that Ekso Bionics Holdings will post -0.81 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Ekso Bionics Holdings, Inc. (EKSO) Lowered to Sell at Zacks Investment Research” was originally published by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another publication, it was stolen and reposted in violation of US and international trademark & copyright laws. The correct version of this article can be viewed at https://www.watchlistnews.com/ekso-bionics-holdings-inc-ekso-lowered-to-sell-at-zacks-investment-research/1708529.html.

Institutional investors and hedge funds have recently modified their holdings of the company. Carl Domino Inc grew its stake in shares of Ekso Bionics Holdings by 74.7% during the 2nd quarter. Carl Domino Inc now owns 82,054 shares of the company’s stock worth $190,000 after acquiring an additional 35,088 shares in the last quarter. Intellectus Partners LLC grew its stake in shares of Ekso Bionics Holdings by 5.3% during the 2nd quarter. Intellectus Partners LLC now owns 105,294 shares of the company’s stock worth $244,000 after acquiring an additional 5,294 shares in the last quarter. National Planning Corp boosted its holdings in shares of Ekso Bionics Holdings by 116.2% in the 2nd quarter. National Planning Corp now owns 234,450 shares of the company’s stock valued at $537,000 after buying an additional 126,000 shares during the last quarter. Finally, Vanguard Group Inc. boosted its holdings in shares of Ekso Bionics Holdings by 32.9% in the 2nd quarter. Vanguard Group Inc. now owns 711,082 shares of the company’s stock valued at $1,650,000 after buying an additional 176,197 shares during the last quarter. 2.85% of the stock is owned by institutional investors.

About Ekso Bionics Holdings

Ekso Bionics Holdings, Inc designs, develops, and sells exoskeletons for use in the healthcare, industrial, military, and consumer markets in North America, Europe, the Middle East, and Africa. The company operates through Medical Devices, Industrial Sales, and Engineering Services segments. It primarily offers Ekso GT, a bionic suit that provides the ability to stand and walk over ground with a reciprocal gait using a cane, crutches, or a walker to individuals with spinal cord injuries, hemiplegia due to stroke, and lower limb paralysis or weakness.

Get a free copy of the Zacks research report on Ekso Bionics Holdings (EKSO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Ekso Bionics Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekso Bionics Holdings Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.